Shots: The P-III CHRONOS-3 study involves assessing of Aliqopa + rituximab vs PBO + rituximab in 458 patients with relapsed indolent NHL who have received at least one or more […]readmore
Tags : Aliqopa
Pharma
Regulatory
Bayer’s Aliqopa (copanlisib) Receives the US FDA’s Breakthrough Therapy Designation
Shots: The BT Designation is based on the P-II CHRONOS-1 study which involves assessing of 25 patients with relapsed or refractory MZL who have received at least two prior therapies […]readmore